Subsidy Information and Financing Scheme MAFFedratinib Capsule 100 mg For the treatment of splenomegaly and/or disease related symptoms in patients with intermediate-2 o... See all × MAFFedratinib Capsule 100 mg For the treatment of splenomegaly and/or disease related symptoms in patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib. MSHLFedratinib Capsule 100 mg For the treatment of splenomegaly and/or disease related symptoms in patients with intermediate-2 o... See all × MSHLFedratinib Capsule 100 mg For the treatment of splenomegaly and/or disease related symptoms in patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib.
Post Marketing Information DHCPL 17/11/2022 Risk of major adverse cardiovascular events, malignancy, thrombosis and death associated with use of Janus Kinase (JAK) inhibitors